Single User License
INR 136060
Site License
INR 272120
Corporate User License
INR 408180

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Metastatic Hepatocellular Carcinoma (HCC)-Pipeline Review, H2 2016

Metastatic Hepatocellular Carcinoma (HCC)-Pipeline Review, H2 2016


  Request for Sample Report

Executive Summary

Metastatic Hepatocellular Carcinoma (HCC)-Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Metastatic Hepatocellular Carcinoma (HCC)-Pipeline Review, H2 2016', provides an overview of the Metastatic Hepatocellular Carcinoma (HCC) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Hepatocellular Carcinoma (HCC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Hepatocellular Carcinoma (HCC) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Metastatic Hepatocellular Carcinoma (HCC)

The report reviews pipeline therapeutics for Metastatic Hepatocellular Carcinoma (HCC) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Metastatic Hepatocellular Carcinoma (HCC) therapeutics and enlists all their major and minor projects

The report assesses Metastatic Hepatocellular Carcinoma (HCC) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Metastatic Hepatocellular Carcinoma (HCC)

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Metastatic Hepatocellular Carcinoma (HCC)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Metastatic Hepatocellular Carcinoma (HCC) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Metastatic Hepatocellular Carcinoma (HCC) Overview 9

Therapeutics Development 10

Pipeline Products for Metastatic Hepatocellular Carcinoma (HCC)-Overview 10

Pipeline Products for Metastatic Hepatocellular Carcinoma (HCC)-Comparative Analysis 11

Metastatic Hepatocellular Carcinoma (HCC)-Therapeutics under Development by Companies 12

Metastatic Hepatocellular Carcinoma (HCC)-Therapeutics under Investigation by Universities/Institutes 14

Metastatic Hepatocellular Carcinoma (HCC)-Pipeline Products Glance 15

Clinical Stage Products 15

Early Stage Products 16

Metastatic Hepatocellular Carcinoma (HCC)-Products under Development by Companies 17

Metastatic Hepatocellular Carcinoma (HCC)-Products under Investigation by Universities/Institutes 18

Metastatic Hepatocellular Carcinoma (HCC)-Companies Involved in Therapeutics Development 19

Acceleron Pharma, Inc. 19

AstraZeneca Plc 20

AVEO Pharmaceuticals, Inc. 21

Celgene Corporation 22

Eisai Co., Ltd. 23

Eli Lilly and Company 24

F. Hoffmann-La Roche Ltd. 25

HanAll Biopharma Co., Ltd. 26

Johnson & Johnson 27

Millennium Pharmaceuticals Inc 28

Mirna Therapeutics, Inc. 29

Molecular Partners AG 30

MolMed S.p.A. 31

Novartis AG 32

OncoMed Pharmaceuticals, Inc. 33

Pfizer Inc. 34

PharmAbcine, Inc. 35

Verlyx Pharma Inc. 36

Metastatic Hepatocellular Carcinoma (HCC)-Therapeutics Assessment 37

Assessment by Monotherapy Products 37

Assessment by Target 38

Assessment by Mechanism of Action 41

Assessment by Route of Administration 44

Assessment by Molecule Type 46

Drug Profiles 48

AV-203-Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

AZD-9150-Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

CC-122-Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Cellular Immunotherapy for Metastatic Hepatocellular Carcinoma-Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

codrituzumab-Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

crizotinib-Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

dalantercept-Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

emibetuzumab-Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

erdafitinib-Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

golvatinib tartrate-Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

HL-143-Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

ipafricept-Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

LY-3039478-Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

LY-3127804-Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

MP-0250-Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

MRX-34-Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

NGR-hTNF-Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

OSU-2S-Drug Profile 95

Product Description 95

Mechanism Of Action 95

R&D Progress 95

palbociclib-Drug Profile 96

Product Description 96

Mechanism Of Action 96

R&D Progress 96

pasireotide-Drug Profile 106

Product Description 106

Mechanism Of Action 106

R&D Progress 106

pentamidine isethionate-Drug Profile 110

Product Description 110

Mechanism Of Action 110

R&D Progress 110

PF-04518600-Drug Profile 112

Product Description 112

Mechanism Of Action 112

R&D Progress 112

PTX-9908-Drug Profile 113

Product Description 113

Mechanism Of Action 113

R&D Progress 113

sapanisertib-Drug Profile 114

Product Description 114

Mechanism Of Action 114

R&D Progress 114

sonidegib phosphate-Drug Profile 117

Product Description 117

Mechanism Of Action 117

R&D Progress 117

temsirolimus-Drug Profile 122

Product Description 122

Mechanism Of Action 122

R&D Progress 122

TTAC-0001-Drug Profile 124

Product Description 124

Mechanism Of Action 124

R&D Progress 124

utomilumab-Drug Profile 125

Product Description 125

Mechanism Of Action 125

R&D Progress 125

Metastatic Hepatocellular Carcinoma (HCC)-Dormant Projects 127

Metastatic Hepatocellular Carcinoma (HCC)-Discontinued Products 128

Metastatic Hepatocellular Carcinoma (HCC)-Product Development Milestones 129

Featured News & Press Releases 129

Jul 30, 2013: Mirna Therapeutics Announces Important Expansion of microRNA Patent Portfolio 129

May 13, 2013: Marina Biotech's Licensee Mirna Therapeutics Initiates Phase I Clinical Trial Of Anticancer Drug MRX34 129

Appendix 130

Methodology 130

Coverage 130

Secondary Research 130

Primary Research 130

Expert Panel Validation 130

Contact Us 130

Disclaimer 131

List of Figures

Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC), H2 2016 10

Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC)-Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Comparative Analysis by Clinical Stage Development, H2 2016 15

Comparative Analysis by Early Stage Products, H2 2016 16

Assessment by Monotherapy Products, H2 2016 37

Number of Products by Top 10 Targets, H2 2016 38

Number of Products by Stage and Top 10 Targets, H2 2016 38

Number of Products by Top 10 Mechanism of Actions, H2 2016 41

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 41

Number of Products by Routes of Administration, H2 2016 44

Number of Products by Stage and Routes of Administration, H2 2016 44

Number of Products by Molecule Types, H2 2016 46

Number of Products by Stage and Molecule Types, H2 2016 46

List of Tables

Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC), H2 2016 10

Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC)-Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Comparative Analysis by Clinical Stage Development, H2 2016 15

Comparative Analysis by Early Stage Development, H2 2016 16

Products under Development by Companies, H2 2016 17

Products under Investigation by Universities/Institutes, H2 2016 18

Metastatic Hepatocellular Carcinoma (HCC)-Pipeline by Acceleron Pharma, Inc., H2 2016 19

Metastatic Hepatocellular Carcinoma (HCC)-Pipeline by AstraZeneca Plc, H2 2016 20

Metastatic Hepatocellular Carcinoma (HCC)-Pipeline by AVEO Pharmaceuticals, Inc., H2 2016 21

Metastatic Hepatocellular Carcinoma (HCC)-Pipeline by Celgene Corporation, H2 2016 22

Metastatic Hepatocellular Carcinoma (HCC)-Pipeline by Eisai Co., Ltd., H2 2016 23

Metastatic Hepatocellular Carcinoma (HCC)-Pipeline by Eli Lilly and Company, H2 2016 24

Metastatic Hepatocellular Carcinoma (HCC)-Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 25

Metastatic Hepatocellular Carcinoma (HCC)-Pipeline by HanAll Biopharma Co., Ltd., H2 2016 26

Metastatic Hepatocellular Carcinoma (HCC)-Pipeline by Johnson & Johnson, H2 2016 27

Metastatic Hepatocellular Carcinoma (HCC)-Pipeline by Millennium Pharmaceuticals Inc, H2 2016 28

Metastatic Hepatocellular Carcinoma (HCC)-Pipeline by Mirna Therapeutics, Inc., H2 2016 29

Metastatic Hepatocellular Carcinoma (HCC)-Pipeline by Molecular Partners AG, H2 2016 30

Metastatic Hepatocellular Carcinoma (HCC)-Pipeline by MolMed S.p.A., H2 2016 31

Metastatic Hepatocellular Carcinoma (HCC)-Pipeline by Novartis AG, H2 2016 32

Metastatic Hepatocellular Carcinoma (HCC)-Pipeline by OncoMed Pharmaceuticals, Inc., H2 2016 33

Metastatic Hepatocellular Carcinoma (HCC)-Pipeline by Pfizer Inc., H2 2016 34

Metastatic Hepatocellular Carcinoma (HCC)-Pipeline by PharmAbcine, Inc., H2 2016 35

Metastatic Hepatocellular Carcinoma (HCC)-Pipeline by Verlyx Pharma Inc., H2 2016 36

Assessment by Monotherapy Products, H2 2016 37

Number of Products by Stage and Target, H2 2016 39

Number of Products by Stage and Mechanism of Action, H2 2016 42

Number of Products by Stage and Route of Administration, H2 2016 45

Number of Products by Stage and Molecule Type, H2 2016 47

Metastatic Hepatocellular Carcinoma (HCC)-Dormant Projects, H2 2016 127

Metastatic Hepatocellular Carcinoma (HCC)-Discontinued Products, H2 2016 128

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Acceleron Pharma, Inc.

AstraZeneca Plc

AVEO Pharmaceuticals, Inc.

Celgene Corporation

Eisai Co., Ltd.

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

HanAll Biopharma Co., Ltd.

Johnson & Johnson

Millennium Pharmaceuticals Inc

Mirna Therapeutics, Inc.

Molecular Partners AG

MolMed S.p.A.

Novartis AG

OncoMed Pharmaceuticals, Inc.

Pfizer Inc.

PharmAbcine, Inc.

Verlyx Pharma Inc.

Metastatic Hepatocellular Carcinoma (HCC) Therapeutic Products under Development, Key Players in Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, Metastatic Hepatocellular Carcinoma (HCC) Pipeline Overview, Metastatic Hepatocellular Carcinoma (HCC) Pipeline, Metastatic Hepatocellular Carcinoma (HCC) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com